You are looking at 141 - 150 of 307 items for :

  • Refine by Content Type: All x
Clear All Modify Search
Steve Doran

They say a brand should be revisited every 10 years. ASN last rebranded in 2008 and since then, the society has gone through drastic changes. Membership has increased by 138%. ASN added two publications (ASN Kidney News and e-newsletter In the Loop) as well as launched a new self-assessment program (KSAP). But most important, ASN not only established a foundation during that time, but also created three public-private partnerships with different government agencies. These include:

• Kidney Health Initiative (KHI) with the U.S. Food and Drug Administration.

• Nephrologists Transforming Dialysis Safety (NTDS) with the Centers for Disease

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is an effective treatment for anemia both in nondialysis patients with chronic kidney disease (CKD) and in long-term dialysis patients, according to a pair of industry-sponsored trials recently published in the New England Journal of Medicine (NEJM).

Nondialysis trial

The nondialysis CKD trial included 154 patients who were enrolled at 29 sites in China. All the patients with CKD had baseline hemoglobin levels of 7.0 to less than 10 g/dL. None of the patients had received erythropoiesis-stimulating agents for at least the previous 5 weeks.

The researchers note that in China,

Rasheed A. Gbadegesin, MD, MBBS

Rasheed A. Gbadegesin, MD, MBBS, will discuss “Genome-Wide Association Study (GWAS)–Derived Targets for Glomerular Diseases” in the Michelle P. Winn, MD, Endowed Lectureship on Friday, Nov. 8.

Dr. Gbadegesin is a professor of pediatrics in the division of nephrology at Duke University and an investigator at the Duke Molecular Physiology Institute in Durham, N.C. The lectureship’s namesake, Dr. Michelle Winn, recruited Dr. Gbadegesin to Duke University and played a vital role as his main mentor until her death in 2014.

Dr. Gbadegesin’s research is aimed at understanding the genetic basis, pathogenesis, and determinants of variable

A leading researcher in applying DNA sequencing to diagnostics will present the Robert W. Schrier, MD, Endowed Lectureship on Friday, Nov. 8. Ali G. Gharavi, MD, will speak on “Diagnostic Exome Sequencing in Chronic Kidney Disease (CKD).”

Ali G. Gharavi, MD

Dr. Gharavi is the Jay Meltzer Professor of Nephrology and Hypertension and chief of the division of nephrology at the Columbia University Irving Medical Center in New York City. He is also director of the Center for Medical Genetics and Genomics at Columbia University.

Dr. Gharavi’s research is focused on the molecular genetics of kidney diseases. His work has

Patients face a variety of barriers to transplantation, and a specialist will talk about the challenges of “Educating Patients and Practitioners About the Benefits of Transplantation” in the Burton D. Rose, MD, Endowed Lectureship on Friday, Nov. 8.

Bertram L. Kasiske, MD

The speaker will be Bertram L. Kasiske, MD, professor of medicine at the University of Minnesota in Minneapolis and director of the Scientific Registry of Transplant Recipients (SRTR), the federal registry of solid organ transplants in the U.S.

He is former deputy director of the U.S. Renal Data System, former co-chair of Kidney Disease: Improving Global Outcomes, and

In July 2019, President Donald Trump signed an executive order to launch the Advancing American Kidney Health (AAKH) initiative, creating an unprecedented focus on kidney disease, while also shifting the focus to kidney health. The executive order articulates a unified strategy that will guide the efforts of ASN and the kidney community to improve every aspect of kidney care, research, and education.

For more than a decade, ASN has worked to build bipartisan support throughout all parts of the U.S. government—including the White House, all relevant agencies, and both chambers of Congress—for people with kidney disease, their caregivers, and researchers

The Donald W. Seldin Young Investigator Award will be presented to Samir M. Parikh, MD, who will speak on “Prospects for NAD+ Based Therapies in Acute Kidney Injury” on Friday, Nov. 8.

Samir M. Parikh, MD

Dr. Parikh is associate professor of medicine and associate vice chair for research at Harvard Medical School. He is also director of the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center.

His research is focused on molecular mechanisms underlying acute kidney injury and sepsis. In recent studies, the Parikh laboratory has implicated mitochondrial maintenance via PGC1α and NAD+ as a novel

Dyer Diskin, Graham Abra, Wael Hussein, and Brigitte Schiller
Case presentation

A 71-year-old woman began using three-times-weekly hemodialysis (HD) 8 months ago and reports worsening fatigue, along with increasing difficulty with her activities of daily living. She is fearful that loss of independence will require her to move to a nursing facility. As her renal failure progressed over the past year she experienced complications that required repeated hospitalizations. After each discharge, she has reported feeling even weaker. She has declined prior offers of inpatient rehabilitation and has struggled with coordinating in-home physical therapy. She wants to exercise and improve her physical function, but she has a fear of falling.

Jorge Cerdá

Acute kidney injury (AKI) does not discriminate in its impact. From the very young to the elderly, it can strike at any time, stems from a wide variety of causes, and demonstrates a complex variety of symptoms. The resulting kidney damage is often severe and life-threatening. Those who recover from AKI have a greater likelihood of important health consequences including recurrent AKI, progression to chronic kidney disease or end stage kidney disease, disability, and death.

Given the current state, in addition to developing newer paradigms and treatments, improvement in AKI outcomes will require a very large discussion involving all the


As a global organization, we show up as one therapeutic area—cardiovascular, renal, and metabolism or “CVRM.” With our expertise over time in this space, we recognize that science has uncovered commonalities between cardiovascular, renal, and metabolic diseases and their associated complications. Yet in many cases, each condition is managed in isolation.

Our portfolio approach allows us to uncover the interconnectedness of these diseases and additional comorbidities to treat the patient as a whole. We